Randomized trials finding interactions with APOE4 suggest that such AD carriers could also potentially present favorable imaging and cognitive outcomes with high dose docosahexaenoic acid supplementation treatments (Arellanes et al., 2020). Here, APOE is linked to Alzheimer disease.